According to the World Health Organization, roughly 800,000 people worldwide die from suicide annually. Among members of the general population who have suicidal thoughts, one out of three will attempt suicide. Out of 286 suicide attempts, one will result in death. Results from a College of Medicine study suggest that for every two people living with HIV/AIDS who have suicidal thoughts, one person will attempt suicide. Among this population, out of 13 suicide attempts, one will result in death.
Analyzing data from more than 185,000 adults living with HIV/AIDS worldwide, the researchers examined risk factors and incidences of attempted and completed suicides among this population. They found that not only is suicidal ideation higher, but people living with HIV/AIDS were 100 times more likely to die by suicide compared to the general population.
“There is an urgent need to prioritize mental health screening and care into all HIV testing and treatment settings,” said Dr. Paddy Ssentongo, researcher and epidemiology doctoral student. “Suicide risk should be assessed in all HIV patients, especially in those who are newly-diagnosed and those with advanced disease.”
According to the findings, people living with HIV/AIDS in North America are 50 times more likely to commit suicide compared to those living in Europe. Similarly, North America, South America and Australia have the highest rates of suicide attempts in people living with HIV/AIDS. The researchers also found that the risk of suicide was high for both newly diagnosed individuals and those whose illness progressed to AIDS.
The researchers noted that several possible factors may contribute to the increased risk of suicide among people living with HIV/AIDS, including advanced disease, neurological changes and societal stigmas. On the other hand, data from the study showed that patients being treated with antiretroviral therapy were less likely to commit suicide. The researchers said the study reveals the importance of mental health screenings and interventions for people living with HIV/AIDS.
Matt Pelton, Matthew Ciarletta, Holly Wisnousky, Nicholas Lazzara, Monica Manglani, Djibril Ba, Vernon Chinchillli and Anna Ssentongo of Penn State College of Medicine and Ping Du of Takeda Pharmaceuticals also contributed to this research. The researchers declare no conflict of interest.
Paddy Ssentongo was supported by a U.S. National Institutes of Health Director’s Transformative Award (award number 1R01AI145057).
Read the full study in General Psychiatry.
About Penn State College of Medicine
Located on the campus of Penn State Health Milton S. Hershey Medical Center in Hershey, Pa., Penn State College of Medicine boasts a portfolio of more than $100 million in funded research. Projects range from development of artificial organs and advanced diagnostics to groundbreaking cancer treatments and understanding the fundamental causes of disease. Enrolling its first students in 1967, the College of Medicine has more than 1,700 students and trainees in medicine, nursing, the health professions and biomedical research on its two campuses.